Novo Nordisk study shows benefits of Xultophy compared to insulin

Novo Nordisk has announced the findings of a new study that further underline the diabetes management benefits of its drug Xultophy.

In the DUAL VII clinical trial, once-daily Xultophy was shown to be a better option for managing diabetes than multiple daily injections of insulin among people with type 2 diabetes whose blood sugar was not controlled on insulin glargine with metformin.

In addition, it was shown that more people preferred to stay on Xultophy compared with basal-bolus insulin therapy, with Xultophy patients also reporting better experiences for all diabetes-specific factors, as well as in terms of mental health.

Mads Krogsgaard Thomsen, executive vice-president and chief science officer of Novo Nordisk, said: "We are very pleased to see that Xultophy not only helps people with type 2 diabetes reach their blood glucose targets while reducing the risk of hypoglycaemia and helping them to lose weight, but does this in a simple way."

Xultophy is a once-daily single injection fixed-ratio combination of long-acting insulin degludec and the glucagon-like peptide-1 receptor agonist liraglutide, offering both medications in a single pen.

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.